DelveInsight Business Research LLP

Albany, NY -- (SBWIRE) -- 11/30/2018 -- DelveInsight has announced the addition of the "Short Bowel Syndrome (SBS) - Market Insights, Epidemiology and Market Forecast- 2027" drug pipelines to their offering.

The Report provides the current treatment practices, emerging drugs, the market share of the individual therapies, current and forecasted market size of Short Bowel Syndrome from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.

Short Bowel Syndrome is the malabsorptive condition which occurs due to the massive resection of the small intestine. It also occurs due to the surgical resection of the small intestine for Crohn disease, trauma, malignancy, radiation, or mesenteric ischemia. It is the most common cause of intestinal failure in children. Short bowel syndrome is characterized by signs and symptoms such as cramping, fatigue, weakness, weight loss and malnutrition and Heartburn.

Approximately 10,000–20,000 people are suffering from Short Bowel Syndrome in the United States. As per the National Organization of Rare Disease, Short Bowel Syndrome affects males and females in equal numbers. Treatment of Short Bowel Syndrome depends on the specific symptoms observed among the patients. The therapeutic market is driven by the use of proton pump inhibitors, choleretic agents, anti-secretin agents and teduglutide for the treatment of Short Bowel Syndrome. Proton pump inhibitors are recommended for treating too much gastric acid secretion among patients with Short Bowel Syndrome. Choleretic agents are effective in preventing liver disease and improving bile flow. Anti-secretin agents are used for reducing the gastric acid in the intestine. Physicians recommend growth hormones for improving the intestinal absorption among the patients.

Geography Covered

- The United States

- EU5 (Germany, France, Italy, Spain and the United Kingdom)

- Japan

Study Period: 2016-2027

Report Scope
This report will help to develop Business Strategies by understanding the trends shaping and driving Short Bowel Syndrome market. It organizes sales and marketing efforts by identifying the best opportunities for Short Bowel Syndrome market. It helps to understand the future market competition in the Short Bowel Syndrome market.

For more information on this press release visit: http://www.sbwire.com/press-releases/short-bowel-syndrome-sbs-market-insights-epidemiology-1095852.htm